Novo Nordisk has announced plans to take legal action against Hims & Hers following the telehealth company's release of a generic version of a weight loss medication similar to Wegovy, priced at $49—significantly below Novo's $149 retail price for the branded product.
- Hims & Hers launched a $49 generic version of a Wegovy-like weight loss drug
- Novo Nordisk’s branded version is priced at $149 per month
- Novo Nordisk has confirmed it will pursue legal action
- The $49 price represents a 67% reduction compared to Novo’s retail cost
- The dispute centers on potential intellectual property infringement
- The outcome could affect pricing trends and insurance coverage in the GLP-1 drug market
Novo Nordisk is escalating its response to competitive pricing in the weight loss drug market by confirming it will initiate legal proceedings against Hims & Hers over the launch of a $49 generic version of a GLP-1 receptor agonist drug. The product, marketed as a biosimilar to Novo’s Wegovy, is positioned as a more affordable alternative to the original branded medication, which retails at $149 per monthly dose. The move marks a direct challenge to Novo’s pricing strategy and intellectual property claims in the fast-growing obesity treatment segment. The $49 price point represents a 67% reduction from Novo’s current retail cost, underscoring a growing trend of direct-to-consumer telehealth platforms disrupting traditional pharmaceutical pricing models. Hims & Hers’ entry into the market highlights increased competition in the weight loss space, where demand for accessible treatments has surged despite high sticker prices. Novo Nordisk has not publicly disclosed its patent status on the specific formulation in question, but its decision to pursue litigation suggests concerns over potential infringement of intellectual property rights. Market analysts note that such legal actions could influence both pricing dynamics and patient access. If Novo prevails, it may set a precedent for protecting branded drug pricing in the face of lower-cost generics. Conversely, a favorable outcome for Hims & Hers could accelerate the adoption of affordable alternatives. The outcome may also affect investor sentiment toward both companies, particularly given the projected $30 billion global market for GLP-1 drugs by 2030. Healthcare providers and payers are closely monitoring the case, as it could determine whether insurers will shift coverage toward lower-cost generic versions. The legal dispute underscores a broader industry shift toward price transparency and competition, particularly as consumer-focused digital health platforms expand their pharmaceutical offerings.